ProCE Banner Activity

Podcast Pearls
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions

PDF
Download this short summary of key points from a FAQ podcast on managing patients with T-cell lymphomas using biomarker-driven therapies and the latest clinical evidence.

Released: January 31, 2022

Expiration: January 30, 2023

No longer available for credit.

Share

Faculty

Francine Foss

Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Barbara Pro

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Kyowa Kirin Inc

Seagen Inc.

Takeda Oncology

Faculty Disclosure

Primary Author

Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Francine Foss, MD, has disclosed that she has received consulting fees from Mallinkrodt and Miragen and fees for non-CME/CE services from Seattle Genetics and Spectrum.

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from ADCT Therapeutics, Affimed, Aileron, Angimmune, BeiGene, Corvus, Forty-Seven, Infinity/Verastem, Innate Pharma, Kura, Kyowa Hakka Kirin, Merck, Millennium/Takeda, Miragen, Mundipharma, Portola, Seattle Genetics, and Syros and funds for research support from ADCT Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Versatem, Kyowa Hakka Kirin, Millennium/Takeda, Seattle Genetics, and Trillium.

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Barbara Pro, MD, has disclosed that she has received funds for research support from Celgene, Seattle Genetics, and Takeda and consulting fees from Celgene, Kyowa, Portola, Seattle Genetics, and Takeda.